nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2C19—epilepsy syndrome	0.171	0.574	CbGaD
Arformoterol—CYP2D6—epilepsy syndrome	0.127	0.426	CbGaD
Arformoterol—CYP2A6—Amobarbital—epilepsy syndrome	0.041	0.0897	CbGbCtD
Arformoterol—CYP2A6—Propofol—epilepsy syndrome	0.0306	0.0669	CbGbCtD
Arformoterol—CYP2A6—Phenobarbital—epilepsy syndrome	0.0292	0.0639	CbGbCtD
Arformoterol—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.0241	0.0527	CbGbCtD
Arformoterol—CYP2C19—Felbamate—epilepsy syndrome	0.0224	0.049	CbGbCtD
Arformoterol—CYP2C19—Trimethadione—epilepsy syndrome	0.0224	0.049	CbGbCtD
Arformoterol—CYP2A6—Valproic Acid—epilepsy syndrome	0.0219	0.0478	CbGbCtD
Arformoterol—CYP2C19—Fosphenytoin—epilepsy syndrome	0.0211	0.046	CbGbCtD
Arformoterol—CYP2C9—Trimethadione—epilepsy syndrome	0.0186	0.0407	CbGbCtD
Arformoterol—CYP2C19—Clobazam—epilepsy syndrome	0.0183	0.0399	CbGbCtD
Arformoterol—CYP2C9—Fosphenytoin—epilepsy syndrome	0.0175	0.0383	CbGbCtD
Arformoterol—CYP2C19—Carbamazepine—epilepsy syndrome	0.0151	0.0331	CbGbCtD
Arformoterol—CYP2C19—Primidone—epilepsy syndrome	0.0141	0.0309	CbGbCtD
Arformoterol—CYP2C19—Phenytoin—epilepsy syndrome	0.0136	0.0297	CbGbCtD
Arformoterol—CYP2C19—Propofol—epilepsy syndrome	0.0127	0.0277	CbGbCtD
Arformoterol—CYP2C9—Carbamazepine—epilepsy syndrome	0.0126	0.0275	CbGbCtD
Arformoterol—CYP2C19—Phenobarbital—epilepsy syndrome	0.0121	0.0264	CbGbCtD
Arformoterol—CYP2C9—Primidone—epilepsy syndrome	0.0117	0.0257	CbGbCtD
Arformoterol—CYP2C19—Diazepam—epilepsy syndrome	0.0115	0.0251	CbGbCtD
Arformoterol—CYP2C9—Phenytoin—epilepsy syndrome	0.0113	0.0247	CbGbCtD
Arformoterol—CYP2C19—Zonisamide—epilepsy syndrome	0.0112	0.0245	CbGbCtD
Arformoterol—CYP2C9—Propofol—epilepsy syndrome	0.0105	0.023	CbGbCtD
Arformoterol—CYP2C9—Phenobarbital—epilepsy syndrome	0.0101	0.022	CbGbCtD
Arformoterol—CYP2D6—Propofol—epilepsy syndrome	0.00962	0.021	CbGbCtD
Arformoterol—CYP2C9—Diazepam—epilepsy syndrome	0.00953	0.0208	CbGbCtD
Arformoterol—CYP2C19—Valproic Acid—epilepsy syndrome	0.00904	0.0198	CbGbCtD
Arformoterol—CYP2C19—Topiramate—epilepsy syndrome	0.00816	0.0178	CbGbCtD
Arformoterol—CYP2C9—Valproic Acid—epilepsy syndrome	0.00752	0.0164	CbGbCtD
Arformoterol—Formoterol—CYP2C19—epilepsy syndrome	0.000257	0.438	CrCbGaD
Arformoterol—Formoterol—CYP2D6—epilepsy syndrome	0.000191	0.325	CrCbGaD
Arformoterol—Labetalol—CYP2D6—epilepsy syndrome	0.000139	0.237	CrCbGaD
Arformoterol—Rhinitis—Topiramate—epilepsy syndrome	4.93e-05	0.000255	CcSEcCtD
Arformoterol—Back pain—Gabapentin—epilepsy syndrome	4.92e-05	0.000254	CcSEcCtD
Arformoterol—Headache—Fosphenytoin—epilepsy syndrome	4.92e-05	0.000254	CcSEcCtD
Arformoterol—Nervous system disorder—Valproic Acid—epilepsy syndrome	4.91e-05	0.000254	CcSEcCtD
Arformoterol—Palpitations—Pregabalin—epilepsy syndrome	4.9e-05	0.000253	CcSEcCtD
Arformoterol—Asthenia—Phenytoin—epilepsy syndrome	4.9e-05	0.000253	CcSEcCtD
Arformoterol—Nausea—Midazolam—epilepsy syndrome	4.89e-05	0.000253	CcSEcCtD
Arformoterol—Muscle spasms—Gabapentin—epilepsy syndrome	4.89e-05	0.000253	CcSEcCtD
Arformoterol—Tachycardia—Valproic Acid—epilepsy syndrome	4.89e-05	0.000253	CcSEcCtD
Arformoterol—Diarrhoea—Zonisamide—epilepsy syndrome	4.88e-05	0.000252	CcSEcCtD
Arformoterol—Pharyngitis—Topiramate—epilepsy syndrome	4.88e-05	0.000252	CcSEcCtD
Arformoterol—Asthenia—Oxcarbazepine—epilepsy syndrome	4.87e-05	0.000252	CcSEcCtD
Arformoterol—Pruritus—Clonazepam—epilepsy syndrome	4.86e-05	0.000252	CcSEcCtD
Arformoterol—Vomiting—Vigabatrin—epilepsy syndrome	4.86e-05	0.000251	CcSEcCtD
Arformoterol—Skin disorder—Valproic Acid—epilepsy syndrome	4.86e-05	0.000251	CcSEcCtD
Arformoterol—Urinary tract disorder—Topiramate—epilepsy syndrome	4.85e-05	0.000251	CcSEcCtD
Arformoterol—Oedema peripheral—Topiramate—epilepsy syndrome	4.84e-05	0.00025	CcSEcCtD
Arformoterol—Cough—Pregabalin—epilepsy syndrome	4.84e-05	0.00025	CcSEcCtD
Arformoterol—Pruritus—Phenytoin—epilepsy syndrome	4.83e-05	0.00025	CcSEcCtD
Arformoterol—Connective tissue disorder—Topiramate—epilepsy syndrome	4.83e-05	0.00025	CcSEcCtD
Arformoterol—Nausea—Levetiracetam—epilepsy syndrome	4.83e-05	0.00025	CcSEcCtD
Arformoterol—Rash—Vigabatrin—epilepsy syndrome	4.82e-05	0.000249	CcSEcCtD
Arformoterol—Dizziness—Felbamate—epilepsy syndrome	4.82e-05	0.000249	CcSEcCtD
Arformoterol—Dermatitis—Vigabatrin—epilepsy syndrome	4.82e-05	0.000249	CcSEcCtD
Arformoterol—Urethral disorder—Topiramate—epilepsy syndrome	4.82e-05	0.000249	CcSEcCtD
Arformoterol—Pruritus—Oxcarbazepine—epilepsy syndrome	4.81e-05	0.000249	CcSEcCtD
Arformoterol—Hypersensitivity—Carbamazepine—epilepsy syndrome	4.8e-05	0.000248	CcSEcCtD
Arformoterol—Headache—Vigabatrin—epilepsy syndrome	4.79e-05	0.000248	CcSEcCtD
Arformoterol—Hypertension—Pregabalin—epilepsy syndrome	4.79e-05	0.000248	CcSEcCtD
Arformoterol—Vomiting—Diazepam—epilepsy syndrome	4.79e-05	0.000248	CcSEcCtD
Arformoterol—Tremor—Gabapentin—epilepsy syndrome	4.76e-05	0.000246	CcSEcCtD
Arformoterol—Rash—Diazepam—epilepsy syndrome	4.75e-05	0.000246	CcSEcCtD
Arformoterol—Dermatitis—Diazepam—epilepsy syndrome	4.74e-05	0.000245	CcSEcCtD
Arformoterol—Visual impairment—Topiramate—epilepsy syndrome	4.74e-05	0.000245	CcSEcCtD
Arformoterol—Myalgia—Pregabalin—epilepsy syndrome	4.72e-05	0.000244	CcSEcCtD
Arformoterol—Chest pain—Pregabalin—epilepsy syndrome	4.72e-05	0.000244	CcSEcCtD
Arformoterol—Arthralgia—Pregabalin—epilepsy syndrome	4.72e-05	0.000244	CcSEcCtD
Arformoterol—Ill-defined disorder—Gabapentin—epilepsy syndrome	4.72e-05	0.000244	CcSEcCtD
Arformoterol—Dizziness—Zonisamide—epilepsy syndrome	4.72e-05	0.000244	CcSEcCtD
Arformoterol—Headache—Diazepam—epilepsy syndrome	4.72e-05	0.000244	CcSEcCtD
Arformoterol—Anxiety—Pregabalin—epilepsy syndrome	4.71e-05	0.000243	CcSEcCtD
Arformoterol—Diarrhoea—Clonazepam—epilepsy syndrome	4.7e-05	0.000243	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	4.69e-05	0.000242	CcSEcCtD
Arformoterol—Hypotension—Valproic Acid—epilepsy syndrome	4.68e-05	0.000242	CcSEcCtD
Arformoterol—Asthenia—Carbamazepine—epilepsy syndrome	4.68e-05	0.000242	CcSEcCtD
Arformoterol—Agitation—Gabapentin—epilepsy syndrome	4.67e-05	0.000242	CcSEcCtD
Arformoterol—Diarrhoea—Phenytoin—epilepsy syndrome	4.67e-05	0.000242	CcSEcCtD
Arformoterol—Discomfort—Pregabalin—epilepsy syndrome	4.66e-05	0.000241	CcSEcCtD
Arformoterol—Nausea—Fosphenytoin—epilepsy syndrome	4.66e-05	0.000241	CcSEcCtD
Arformoterol—Diarrhoea—Oxcarbazepine—epilepsy syndrome	4.65e-05	0.00024	CcSEcCtD
Arformoterol—Angioedema—Gabapentin—epilepsy syndrome	4.65e-05	0.00024	CcSEcCtD
Arformoterol—Hypersensitivity—Lamotrigine—epilepsy syndrome	4.64e-05	0.00024	CcSEcCtD
Arformoterol—Vomiting—Felbamate—epilepsy syndrome	4.63e-05	0.00024	CcSEcCtD
Arformoterol—Dry mouth—Pregabalin—epilepsy syndrome	4.62e-05	0.000239	CcSEcCtD
Arformoterol—Pruritus—Carbamazepine—epilepsy syndrome	4.61e-05	0.000238	CcSEcCtD
Arformoterol—Rash—Felbamate—epilepsy syndrome	4.6e-05	0.000238	CcSEcCtD
Arformoterol—Dermatitis—Felbamate—epilepsy syndrome	4.59e-05	0.000237	CcSEcCtD
Arformoterol—Malaise—Gabapentin—epilepsy syndrome	4.59e-05	0.000237	CcSEcCtD
Arformoterol—Headache—Felbamate—epilepsy syndrome	4.57e-05	0.000236	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	4.56e-05	0.000236	CcSEcCtD
Arformoterol—Cardiac disorder—Topiramate—epilepsy syndrome	4.56e-05	0.000236	CcSEcCtD
Arformoterol—Dizziness—Clonazepam—epilepsy syndrome	4.55e-05	0.000235	CcSEcCtD
Arformoterol—Nausea—Vigabatrin—epilepsy syndrome	4.54e-05	0.000235	CcSEcCtD
Arformoterol—Vomiting—Zonisamide—epilepsy syndrome	4.54e-05	0.000235	CcSEcCtD
Arformoterol—Insomnia—Valproic Acid—epilepsy syndrome	4.53e-05	0.000234	CcSEcCtD
Arformoterol—Oedema—Pregabalin—epilepsy syndrome	4.53e-05	0.000234	CcSEcCtD
Arformoterol—Anaphylactic shock—Pregabalin—epilepsy syndrome	4.53e-05	0.000234	CcSEcCtD
Arformoterol—Asthenia—Lamotrigine—epilepsy syndrome	4.52e-05	0.000234	CcSEcCtD
Arformoterol—Dizziness—Phenytoin—epilepsy syndrome	4.52e-05	0.000234	CcSEcCtD
Arformoterol—Rash—Zonisamide—epilepsy syndrome	4.5e-05	0.000233	CcSEcCtD
Arformoterol—Infection—Pregabalin—epilepsy syndrome	4.5e-05	0.000233	CcSEcCtD
Arformoterol—Palpitations—Gabapentin—epilepsy syndrome	4.49e-05	0.000232	CcSEcCtD
Arformoterol—Dermatitis—Zonisamide—epilepsy syndrome	4.49e-05	0.000232	CcSEcCtD
Arformoterol—Dizziness—Oxcarbazepine—epilepsy syndrome	4.49e-05	0.000232	CcSEcCtD
Arformoterol—Nausea—Diazepam—epilepsy syndrome	4.47e-05	0.000231	CcSEcCtD
Arformoterol—Headache—Zonisamide—epilepsy syndrome	4.47e-05	0.000231	CcSEcCtD
Arformoterol—Dyspnoea—Valproic Acid—epilepsy syndrome	4.46e-05	0.000231	CcSEcCtD
Arformoterol—Diarrhoea—Carbamazepine—epilepsy syndrome	4.46e-05	0.000231	CcSEcCtD
Arformoterol—Pruritus—Lamotrigine—epilepsy syndrome	4.46e-05	0.00023	CcSEcCtD
Arformoterol—Somnolence—Valproic Acid—epilepsy syndrome	4.45e-05	0.00023	CcSEcCtD
Arformoterol—Immune system disorder—Topiramate—epilepsy syndrome	4.44e-05	0.00023	CcSEcCtD
Arformoterol—Nervous system disorder—Pregabalin—epilepsy syndrome	4.44e-05	0.00023	CcSEcCtD
Arformoterol—Cough—Gabapentin—epilepsy syndrome	4.44e-05	0.000229	CcSEcCtD
Arformoterol—Mediastinal disorder—Topiramate—epilepsy syndrome	4.43e-05	0.000229	CcSEcCtD
Arformoterol—Tachycardia—Pregabalin—epilepsy syndrome	4.42e-05	0.000228	CcSEcCtD
Arformoterol—Dyspepsia—Valproic Acid—epilepsy syndrome	4.41e-05	0.000228	CcSEcCtD
Arformoterol—Skin disorder—Pregabalin—epilepsy syndrome	4.4e-05	0.000227	CcSEcCtD
Arformoterol—Hypertension—Gabapentin—epilepsy syndrome	4.39e-05	0.000227	CcSEcCtD
Arformoterol—Vomiting—Clonazepam—epilepsy syndrome	4.37e-05	0.000226	CcSEcCtD
Arformoterol—Vomiting—Phenytoin—epilepsy syndrome	4.34e-05	0.000225	CcSEcCtD
Arformoterol—Rash—Clonazepam—epilepsy syndrome	4.34e-05	0.000224	CcSEcCtD
Arformoterol—Dermatitis—Clonazepam—epilepsy syndrome	4.33e-05	0.000224	CcSEcCtD
Arformoterol—Chest pain—Gabapentin—epilepsy syndrome	4.33e-05	0.000224	CcSEcCtD
Arformoterol—Arthralgia—Gabapentin—epilepsy syndrome	4.33e-05	0.000224	CcSEcCtD
Arformoterol—Myalgia—Gabapentin—epilepsy syndrome	4.33e-05	0.000224	CcSEcCtD
Arformoterol—Nausea—Felbamate—epilepsy syndrome	4.33e-05	0.000224	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	4.32e-05	0.000224	CcSEcCtD
Arformoterol—Vomiting—Oxcarbazepine—epilepsy syndrome	4.32e-05	0.000223	CcSEcCtD
Arformoterol—Fatigue—Valproic Acid—epilepsy syndrome	4.32e-05	0.000223	CcSEcCtD
Arformoterol—Anxiety—Gabapentin—epilepsy syndrome	4.31e-05	0.000223	CcSEcCtD
Arformoterol—Dizziness—Carbamazepine—epilepsy syndrome	4.31e-05	0.000223	CcSEcCtD
Arformoterol—Diarrhoea—Lamotrigine—epilepsy syndrome	4.31e-05	0.000223	CcSEcCtD
Arformoterol—Headache—Clonazepam—epilepsy syndrome	4.31e-05	0.000223	CcSEcCtD
Arformoterol—Rash—Phenytoin—epilepsy syndrome	4.31e-05	0.000223	CcSEcCtD
Arformoterol—Mental disorder—Topiramate—epilepsy syndrome	4.31e-05	0.000223	CcSEcCtD
Arformoterol—Dermatitis—Phenytoin—epilepsy syndrome	4.3e-05	0.000222	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	4.3e-05	0.000222	CcSEcCtD
Arformoterol—Rash—Oxcarbazepine—epilepsy syndrome	4.28e-05	0.000221	CcSEcCtD
Arformoterol—Constipation—Valproic Acid—epilepsy syndrome	4.28e-05	0.000221	CcSEcCtD
Arformoterol—Pain—Valproic Acid—epilepsy syndrome	4.28e-05	0.000221	CcSEcCtD
Arformoterol—Dermatitis—Oxcarbazepine—epilepsy syndrome	4.28e-05	0.000221	CcSEcCtD
Arformoterol—Headache—Phenytoin—epilepsy syndrome	4.28e-05	0.000221	CcSEcCtD
Arformoterol—Malnutrition—Topiramate—epilepsy syndrome	4.28e-05	0.000221	CcSEcCtD
Arformoterol—Discomfort—Gabapentin—epilepsy syndrome	4.28e-05	0.000221	CcSEcCtD
Arformoterol—Headache—Oxcarbazepine—epilepsy syndrome	4.26e-05	0.00022	CcSEcCtD
Arformoterol—Nausea—Zonisamide—epilepsy syndrome	4.24e-05	0.000219	CcSEcCtD
Arformoterol—Dry mouth—Gabapentin—epilepsy syndrome	4.23e-05	0.000219	CcSEcCtD
Arformoterol—Hypotension—Pregabalin—epilepsy syndrome	4.23e-05	0.000219	CcSEcCtD
Arformoterol—Tension—Topiramate—epilepsy syndrome	4.2e-05	0.000217	CcSEcCtD
Arformoterol—Dysgeusia—Topiramate—epilepsy syndrome	4.19e-05	0.000217	CcSEcCtD
Arformoterol—Dizziness—Lamotrigine—epilepsy syndrome	4.17e-05	0.000215	CcSEcCtD
Arformoterol—Nervousness—Topiramate—epilepsy syndrome	4.16e-05	0.000215	CcSEcCtD
Arformoterol—Anaphylactic shock—Gabapentin—epilepsy syndrome	4.15e-05	0.000215	CcSEcCtD
Arformoterol—Oedema—Gabapentin—epilepsy syndrome	4.15e-05	0.000215	CcSEcCtD
Arformoterol—Vomiting—Carbamazepine—epilepsy syndrome	4.14e-05	0.000214	CcSEcCtD
Arformoterol—Back pain—Topiramate—epilepsy syndrome	4.14e-05	0.000214	CcSEcCtD
Arformoterol—Feeling abnormal—Valproic Acid—epilepsy syndrome	4.13e-05	0.000213	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	4.12e-05	0.000213	CcSEcCtD
Arformoterol—Infection—Gabapentin—epilepsy syndrome	4.12e-05	0.000213	CcSEcCtD
Arformoterol—Muscle spasms—Topiramate—epilepsy syndrome	4.11e-05	0.000213	CcSEcCtD
Arformoterol—Rash—Carbamazepine—epilepsy syndrome	4.11e-05	0.000213	CcSEcCtD
Arformoterol—Dermatitis—Carbamazepine—epilepsy syndrome	4.11e-05	0.000212	CcSEcCtD
Arformoterol—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	4.09e-05	0.000212	CcSEcCtD
Arformoterol—Insomnia—Pregabalin—epilepsy syndrome	4.09e-05	0.000212	CcSEcCtD
Arformoterol—Nausea—Clonazepam—epilepsy syndrome	4.08e-05	0.000211	CcSEcCtD
Arformoterol—Headache—Carbamazepine—epilepsy syndrome	4.08e-05	0.000211	CcSEcCtD
Arformoterol—Nervous system disorder—Gabapentin—epilepsy syndrome	4.07e-05	0.00021	CcSEcCtD
Arformoterol—Nausea—Phenytoin—epilepsy syndrome	4.06e-05	0.00021	CcSEcCtD
Arformoterol—Tachycardia—Gabapentin—epilepsy syndrome	4.05e-05	0.000209	CcSEcCtD
Arformoterol—Dyspnoea—Pregabalin—epilepsy syndrome	4.04e-05	0.000209	CcSEcCtD
Arformoterol—Nausea—Oxcarbazepine—epilepsy syndrome	4.04e-05	0.000209	CcSEcCtD
Arformoterol—Skin disorder—Gabapentin—epilepsy syndrome	4.03e-05	0.000208	CcSEcCtD
Arformoterol—Somnolence—Pregabalin—epilepsy syndrome	4.02e-05	0.000208	CcSEcCtD
Arformoterol—Tremor—Topiramate—epilepsy syndrome	4.01e-05	0.000207	CcSEcCtD
Arformoterol—Vomiting—Lamotrigine—epilepsy syndrome	4.01e-05	0.000207	CcSEcCtD
Arformoterol—Urticaria—Valproic Acid—epilepsy syndrome	3.98e-05	0.000206	CcSEcCtD
Arformoterol—Rash—Lamotrigine—epilepsy syndrome	3.97e-05	0.000205	CcSEcCtD
Arformoterol—Ill-defined disorder—Topiramate—epilepsy syndrome	3.97e-05	0.000205	CcSEcCtD
Arformoterol—Dermatitis—Lamotrigine—epilepsy syndrome	3.97e-05	0.000205	CcSEcCtD
Arformoterol—Body temperature increased—Valproic Acid—epilepsy syndrome	3.96e-05	0.000205	CcSEcCtD
Arformoterol—Abdominal pain—Valproic Acid—epilepsy syndrome	3.96e-05	0.000205	CcSEcCtD
Arformoterol—Headache—Lamotrigine—epilepsy syndrome	3.95e-05	0.000204	CcSEcCtD
Arformoterol—Agitation—Topiramate—epilepsy syndrome	3.93e-05	0.000203	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.91e-05	0.000202	CcSEcCtD
Arformoterol—Fatigue—Pregabalin—epilepsy syndrome	3.9e-05	0.000202	CcSEcCtD
Arformoterol—Hypotension—Gabapentin—epilepsy syndrome	3.88e-05	0.000201	CcSEcCtD
Arformoterol—Nausea—Carbamazepine—epilepsy syndrome	3.87e-05	0.0002	CcSEcCtD
Arformoterol—Constipation—Pregabalin—epilepsy syndrome	3.87e-05	0.0002	CcSEcCtD
Arformoterol—Pain—Pregabalin—epilepsy syndrome	3.87e-05	0.0002	CcSEcCtD
Arformoterol—Malaise—Topiramate—epilepsy syndrome	3.86e-05	0.0002	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	3.78e-05	0.000196	CcSEcCtD
Arformoterol—Palpitations—Topiramate—epilepsy syndrome	3.78e-05	0.000196	CcSEcCtD
Arformoterol—Insomnia—Gabapentin—epilepsy syndrome	3.75e-05	0.000194	CcSEcCtD
Arformoterol—Nausea—Lamotrigine—epilepsy syndrome	3.74e-05	0.000194	CcSEcCtD
Arformoterol—Cough—Topiramate—epilepsy syndrome	3.73e-05	0.000193	CcSEcCtD
Arformoterol—Feeling abnormal—Pregabalin—epilepsy syndrome	3.73e-05	0.000193	CcSEcCtD
Arformoterol—Gastrointestinal pain—Pregabalin—epilepsy syndrome	3.7e-05	0.000191	CcSEcCtD
Arformoterol—Dyspnoea—Gabapentin—epilepsy syndrome	3.7e-05	0.000191	CcSEcCtD
Arformoterol—Hypertension—Topiramate—epilepsy syndrome	3.69e-05	0.000191	CcSEcCtD
Arformoterol—Somnolence—Gabapentin—epilepsy syndrome	3.69e-05	0.000191	CcSEcCtD
Arformoterol—Hypersensitivity—Valproic Acid—epilepsy syndrome	3.69e-05	0.000191	CcSEcCtD
Arformoterol—Dyspepsia—Gabapentin—epilepsy syndrome	3.65e-05	0.000189	CcSEcCtD
Arformoterol—Myalgia—Topiramate—epilepsy syndrome	3.64e-05	0.000188	CcSEcCtD
Arformoterol—Arthralgia—Topiramate—epilepsy syndrome	3.64e-05	0.000188	CcSEcCtD
Arformoterol—Chest pain—Topiramate—epilepsy syndrome	3.64e-05	0.000188	CcSEcCtD
Arformoterol—Anxiety—Topiramate—epilepsy syndrome	3.63e-05	0.000188	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	3.62e-05	0.000187	CcSEcCtD
Arformoterol—Discomfort—Topiramate—epilepsy syndrome	3.6e-05	0.000186	CcSEcCtD
Arformoterol—Urticaria—Pregabalin—epilepsy syndrome	3.6e-05	0.000186	CcSEcCtD
Arformoterol—Asthenia—Valproic Acid—epilepsy syndrome	3.59e-05	0.000186	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	3.58e-05	0.000185	CcSEcCtD
Arformoterol—Fatigue—Gabapentin—epilepsy syndrome	3.58e-05	0.000185	CcSEcCtD
Arformoterol—Abdominal pain—Pregabalin—epilepsy syndrome	3.58e-05	0.000185	CcSEcCtD
Arformoterol—Body temperature increased—Pregabalin—epilepsy syndrome	3.58e-05	0.000185	CcSEcCtD
Arformoterol—Dry mouth—Topiramate—epilepsy syndrome	3.56e-05	0.000184	CcSEcCtD
Arformoterol—Pain—Gabapentin—epilepsy syndrome	3.55e-05	0.000184	CcSEcCtD
Arformoterol—Constipation—Gabapentin—epilepsy syndrome	3.55e-05	0.000184	CcSEcCtD
Arformoterol—Pruritus—Valproic Acid—epilepsy syndrome	3.54e-05	0.000183	CcSEcCtD
Arformoterol—Oedema—Topiramate—epilepsy syndrome	3.49e-05	0.000181	CcSEcCtD
Arformoterol—Infection—Topiramate—epilepsy syndrome	3.47e-05	0.000179	CcSEcCtD
Arformoterol—Diarrhoea—Valproic Acid—epilepsy syndrome	3.43e-05	0.000177	CcSEcCtD
Arformoterol—Nervous system disorder—Topiramate—epilepsy syndrome	3.42e-05	0.000177	CcSEcCtD
Arformoterol—Feeling abnormal—Gabapentin—epilepsy syndrome	3.42e-05	0.000177	CcSEcCtD
Arformoterol—Tachycardia—Topiramate—epilepsy syndrome	3.41e-05	0.000176	CcSEcCtD
Arformoterol—Gastrointestinal pain—Gabapentin—epilepsy syndrome	3.39e-05	0.000175	CcSEcCtD
Arformoterol—Skin disorder—Topiramate—epilepsy syndrome	3.39e-05	0.000175	CcSEcCtD
Arformoterol—Hypersensitivity—Pregabalin—epilepsy syndrome	3.33e-05	0.000172	CcSEcCtD
Arformoterol—Dizziness—Valproic Acid—epilepsy syndrome	3.31e-05	0.000171	CcSEcCtD
Arformoterol—Urticaria—Gabapentin—epilepsy syndrome	3.3e-05	0.00017	CcSEcCtD
Arformoterol—Abdominal pain—Gabapentin—epilepsy syndrome	3.28e-05	0.00017	CcSEcCtD
Arformoterol—Body temperature increased—Gabapentin—epilepsy syndrome	3.28e-05	0.00017	CcSEcCtD
Arformoterol—Hypotension—Topiramate—epilepsy syndrome	3.26e-05	0.000169	CcSEcCtD
Arformoterol—Asthenia—Pregabalin—epilepsy syndrome	3.25e-05	0.000168	CcSEcCtD
Arformoterol—Pruritus—Pregabalin—epilepsy syndrome	3.2e-05	0.000166	CcSEcCtD
Arformoterol—Vomiting—Valproic Acid—epilepsy syndrome	3.18e-05	0.000165	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	3.18e-05	0.000165	CcSEcCtD
Arformoterol—Insomnia—Topiramate—epilepsy syndrome	3.16e-05	0.000163	CcSEcCtD
Arformoterol—Rash—Valproic Acid—epilepsy syndrome	3.16e-05	0.000163	CcSEcCtD
Arformoterol—Dermatitis—Valproic Acid—epilepsy syndrome	3.15e-05	0.000163	CcSEcCtD
Arformoterol—Headache—Valproic Acid—epilepsy syndrome	3.14e-05	0.000162	CcSEcCtD
Arformoterol—Dyspnoea—Topiramate—epilepsy syndrome	3.11e-05	0.000161	CcSEcCtD
Arformoterol—Somnolence—Topiramate—epilepsy syndrome	3.1e-05	0.000161	CcSEcCtD
Arformoterol—Diarrhoea—Pregabalin—epilepsy syndrome	3.1e-05	0.00016	CcSEcCtD
Arformoterol—Dyspepsia—Topiramate—epilepsy syndrome	3.07e-05	0.000159	CcSEcCtD
Arformoterol—Hypersensitivity—Gabapentin—epilepsy syndrome	3.06e-05	0.000158	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Topiramate—epilepsy syndrome	3.01e-05	0.000156	CcSEcCtD
Arformoterol—Fatigue—Topiramate—epilepsy syndrome	3.01e-05	0.000156	CcSEcCtD
Arformoterol—Dizziness—Pregabalin—epilepsy syndrome	2.99e-05	0.000155	CcSEcCtD
Arformoterol—Pain—Topiramate—epilepsy syndrome	2.99e-05	0.000154	CcSEcCtD
Arformoterol—Constipation—Topiramate—epilepsy syndrome	2.99e-05	0.000154	CcSEcCtD
Arformoterol—Asthenia—Gabapentin—epilepsy syndrome	2.98e-05	0.000154	CcSEcCtD
Arformoterol—Nausea—Valproic Acid—epilepsy syndrome	2.97e-05	0.000154	CcSEcCtD
Arformoterol—Pruritus—Gabapentin—epilepsy syndrome	2.94e-05	0.000152	CcSEcCtD
Arformoterol—Vomiting—Pregabalin—epilepsy syndrome	2.88e-05	0.000149	CcSEcCtD
Arformoterol—Feeling abnormal—Topiramate—epilepsy syndrome	2.88e-05	0.000149	CcSEcCtD
Arformoterol—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.86e-05	0.000148	CcSEcCtD
Arformoterol—Rash—Pregabalin—epilepsy syndrome	2.85e-05	0.000148	CcSEcCtD
Arformoterol—Dermatitis—Pregabalin—epilepsy syndrome	2.85e-05	0.000147	CcSEcCtD
Arformoterol—Diarrhoea—Gabapentin—epilepsy syndrome	2.84e-05	0.000147	CcSEcCtD
Arformoterol—Headache—Pregabalin—epilepsy syndrome	2.84e-05	0.000147	CcSEcCtD
Arformoterol—Urticaria—Topiramate—epilepsy syndrome	2.77e-05	0.000143	CcSEcCtD
Arformoterol—Abdominal pain—Topiramate—epilepsy syndrome	2.76e-05	0.000143	CcSEcCtD
Arformoterol—Body temperature increased—Topiramate—epilepsy syndrome	2.76e-05	0.000143	CcSEcCtD
Arformoterol—Dizziness—Gabapentin—epilepsy syndrome	2.74e-05	0.000142	CcSEcCtD
Arformoterol—Nausea—Pregabalin—epilepsy syndrome	2.69e-05	0.000139	CcSEcCtD
Arformoterol—Vomiting—Gabapentin—epilepsy syndrome	2.64e-05	0.000136	CcSEcCtD
Arformoterol—Rash—Gabapentin—epilepsy syndrome	2.62e-05	0.000135	CcSEcCtD
Arformoterol—Dermatitis—Gabapentin—epilepsy syndrome	2.61e-05	0.000135	CcSEcCtD
Arformoterol—Headache—Gabapentin—epilepsy syndrome	2.6e-05	0.000134	CcSEcCtD
Arformoterol—Hypersensitivity—Topiramate—epilepsy syndrome	2.57e-05	0.000133	CcSEcCtD
Arformoterol—Asthenia—Topiramate—epilepsy syndrome	2.51e-05	0.00013	CcSEcCtD
Arformoterol—Pruritus—Topiramate—epilepsy syndrome	2.47e-05	0.000128	CcSEcCtD
Arformoterol—Nausea—Gabapentin—epilepsy syndrome	2.47e-05	0.000127	CcSEcCtD
Arformoterol—Diarrhoea—Topiramate—epilepsy syndrome	2.39e-05	0.000124	CcSEcCtD
Arformoterol—Dizziness—Topiramate—epilepsy syndrome	2.31e-05	0.000119	CcSEcCtD
Arformoterol—Vomiting—Topiramate—epilepsy syndrome	2.22e-05	0.000115	CcSEcCtD
Arformoterol—Rash—Topiramate—epilepsy syndrome	2.2e-05	0.000114	CcSEcCtD
Arformoterol—Dermatitis—Topiramate—epilepsy syndrome	2.2e-05	0.000114	CcSEcCtD
Arformoterol—Headache—Topiramate—epilepsy syndrome	2.19e-05	0.000113	CcSEcCtD
Arformoterol—Nausea—Topiramate—epilepsy syndrome	2.07e-05	0.000107	CcSEcCtD
Arformoterol—CYP2C19—Metabolism—ST3GAL3—epilepsy syndrome	1.01e-05	0.000202	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCR3—epilepsy syndrome	1e-05	0.0002	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—HTR2A—epilepsy syndrome	1e-05	0.0002	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CCR5—epilepsy syndrome	1e-05	0.0002	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NT5E—epilepsy syndrome	9.98e-06	0.000199	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALAD—epilepsy syndrome	9.98e-06	0.000199	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ADSL—epilepsy syndrome	9.92e-06	0.000198	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NT5E—epilepsy syndrome	9.89e-06	0.000197	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALAD—epilepsy syndrome	9.89e-06	0.000197	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCR3—epilepsy syndrome	9.82e-06	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—HTR2A—epilepsy syndrome	9.81e-06	0.000196	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NPY—epilepsy syndrome	9.78e-06	0.000195	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ATP2A2—epilepsy syndrome	9.78e-06	0.000195	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GLUL—epilepsy syndrome	9.73e-06	0.000194	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NPY—epilepsy syndrome	9.57e-06	0.000191	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ATP2A2—epilepsy syndrome	9.57e-06	0.000191	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CACNA1D—epilepsy syndrome	9.55e-06	0.000191	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AGT—epilepsy syndrome	9.52e-06	0.00019	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CACNA1A—epilepsy syndrome	9.52e-06	0.00019	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALDH7A1—epilepsy syndrome	9.52e-06	0.00019	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HSPB1—epilepsy syndrome	9.44e-06	0.000188	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CRH—epilepsy syndrome	9.44e-06	0.000188	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL2—epilepsy syndrome	9.44e-06	0.000188	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCL3—epilepsy syndrome	9.44e-06	0.000188	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—OXT—epilepsy syndrome	9.44e-06	0.000188	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CACNA1A—epilepsy syndrome	9.44e-06	0.000188	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALDH7A1—epilepsy syndrome	9.44e-06	0.000188	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ST3GAL3—epilepsy syndrome	9.31e-06	0.000186	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AGT—epilepsy syndrome	9.31e-06	0.000186	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CCR5—epilepsy syndrome	9.31e-06	0.000186	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ST3GAL3—epilepsy syndrome	9.23e-06	0.000184	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CRH—epilepsy syndrome	9.23e-06	0.000184	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL2—epilepsy syndrome	9.23e-06	0.000184	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—OXT—epilepsy syndrome	9.23e-06	0.000184	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCL3—epilepsy syndrome	9.23e-06	0.000184	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HSPB1—epilepsy syndrome	9.23e-06	0.000184	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP2D6—epilepsy syndrome	9.17e-06	0.000183	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ADSL—epilepsy syndrome	9.13e-06	0.000182	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HTR2A—epilepsy syndrome	9.11e-06	0.000182	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CCR5—epilepsy syndrome	9.11e-06	0.000182	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ADSL—epilepsy syndrome	9.05e-06	0.000181	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GLUL—epilepsy syndrome	8.95e-06	0.000179	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TXNRD1—epilepsy syndrome	8.93e-06	0.000178	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HTR2A—epilepsy syndrome	8.91e-06	0.000178	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GLUL—epilepsy syndrome	8.87e-06	0.000177	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PRKCB—epilepsy syndrome	8.8e-06	0.000176	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CACNA1D—epilepsy syndrome	8.78e-06	0.000175	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TSC1—epilepsy syndrome	8.77e-06	0.000175	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTK2B—epilepsy syndrome	8.77e-06	0.000175	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ADRA2A—epilepsy syndrome	8.73e-06	0.000174	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CACNA1D—epilepsy syndrome	8.71e-06	0.000174	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—BCHE—epilepsy syndrome	8.69e-06	0.000173	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AQP1—epilepsy syndrome	8.67e-06	0.000173	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AGT—epilepsy syndrome	8.64e-06	0.000173	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PRKCB—epilepsy syndrome	8.6e-06	0.000172	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TSC1—epilepsy syndrome	8.58e-06	0.000171	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTK2B—epilepsy syndrome	8.58e-06	0.000171	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCR2—epilepsy syndrome	8.53e-06	0.00017	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SST—epilepsy syndrome	8.53e-06	0.00017	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NTRK2—epilepsy syndrome	8.53e-06	0.00017	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—DUSP6—epilepsy syndrome	8.46e-06	0.000169	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AGT—epilepsy syndrome	8.46e-06	0.000169	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADRA2A—epilepsy syndrome	8.35e-06	0.000167	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NTRK2—epilepsy syndrome	8.35e-06	0.000167	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SST—epilepsy syndrome	8.35e-06	0.000167	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCR2—epilepsy syndrome	8.35e-06	0.000167	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	8.33e-06	0.000166	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PLAT—epilepsy syndrome	8.32e-06	0.000166	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—SLC2A1—epilepsy syndrome	8.29e-06	0.000165	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—DUSP6—epilepsy syndrome	8.28e-06	0.000165	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TXNRD1—epilepsy syndrome	8.22e-06	0.000164	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PLCB1—epilepsy syndrome	8.2e-06	0.000164	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ADRA2A—epilepsy syndrome	8.17e-06	0.000163	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—TH—epilepsy syndrome	8.17e-06	0.000163	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TXNRD1—epilepsy syndrome	8.15e-06	0.000163	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PLAT—epilepsy syndrome	8.14e-06	0.000162	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL12—epilepsy syndrome	8.02e-06	0.00016	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BDKRB2—epilepsy syndrome	8.02e-06	0.00016	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—POMC—epilepsy syndrome	8.01e-06	0.00016	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PRKCB—epilepsy syndrome	7.99e-06	0.000159	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AQP1—epilepsy syndrome	7.98e-06	0.000159	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6ST—epilepsy syndrome	7.96e-06	0.000159	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AQP1—epilepsy syndrome	7.91e-06	0.000158	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUNB—epilepsy syndrome	7.88e-06	0.000157	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CNR1—epilepsy syndrome	7.88e-06	0.000157	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL12—epilepsy syndrome	7.85e-06	0.000157	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BDKRB2—epilepsy syndrome	7.85e-06	0.000157	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PLCB1—epilepsy syndrome	7.85e-06	0.000157	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CHRM3—epilepsy syndrome	7.84e-06	0.000157	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—KCNJ11—epilepsy syndrome	7.84e-06	0.000157	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—POMC—epilepsy syndrome	7.84e-06	0.000156	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PRKCB—epilepsy syndrome	7.81e-06	0.000156	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6ST—epilepsy syndrome	7.78e-06	0.000155	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUNB—epilepsy syndrome	7.7e-06	0.000154	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CNR1—epilepsy syndrome	7.7e-06	0.000154	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HTR7—epilepsy syndrome	7.68e-06	0.000153	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PLCB1—epilepsy syndrome	7.68e-06	0.000153	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	7.59e-06	0.000152	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HTR7—epilepsy syndrome	7.52e-06	0.00015	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HBEGF—epilepsy syndrome	7.46e-06	0.000149	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT3—epilepsy syndrome	7.32e-06	0.000146	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	7.3e-06	0.000146	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HBEGF—epilepsy syndrome	7.3e-06	0.000146	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—POMC—epilepsy syndrome	7.28e-06	0.000145	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	7.21e-06	0.000144	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	7.21e-06	0.000144	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT3—epilepsy syndrome	7.16e-06	0.000143	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	7.16e-06	0.000143	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADAM10—epilepsy syndrome	7.15e-06	0.000143	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CHRM3—epilepsy syndrome	7.15e-06	0.000143	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—KCNJ11—epilepsy syndrome	7.15e-06	0.000143	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CCL2—epilepsy syndrome	7.12e-06	0.000142	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—POMC—epilepsy syndrome	7.12e-06	0.000142	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ADAM10—epilepsy syndrome	7e-06	0.00014	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CCL2—epilepsy syndrome	6.96e-06	0.000139	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—HMOX1—epilepsy syndrome	6.82e-06	0.000136	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—S100B—epilepsy syndrome	6.76e-06	0.000135	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CAT—epilepsy syndrome	6.73e-06	0.000134	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SOCS3—epilepsy syndrome	6.7e-06	0.000134	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDC42—epilepsy syndrome	6.68e-06	0.000133	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	6.66e-06	0.000133	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—S100B—epilepsy syndrome	6.62e-06	0.000132	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SOCS3—epilepsy syndrome	6.55e-06	0.000131	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ABCB1—epilepsy syndrome	6.54e-06	0.000131	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDC42—epilepsy syndrome	6.54e-06	0.00013	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	6.53e-06	0.00013	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AVP—epilepsy syndrome	6.47e-06	0.000129	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ABCG2—epilepsy syndrome	6.39e-06	0.000128	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AVP—epilepsy syndrome	6.33e-06	0.000126	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP11A1—epilepsy syndrome	6.19e-06	0.000124	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	6.15e-06	0.000123	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HES1—epilepsy syndrome	6.12e-06	0.000122	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GPX1—epilepsy syndrome	6.08e-06	0.000121	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HES1—epilepsy syndrome	5.98e-06	0.000119	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FYN—epilepsy syndrome	5.95e-06	0.000119	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—H2AFX—epilepsy syndrome	5.93e-06	0.000118	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MEF2C—epilepsy syndrome	5.92e-06	0.000118	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	5.88e-06	0.000117	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	5.83e-06	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FYN—epilepsy syndrome	5.82e-06	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—H2AFX—epilepsy syndrome	5.8e-06	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MEF2C—epilepsy syndrome	5.79e-06	0.000116	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	5.73e-06	0.000114	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—YWHAZ—epilepsy syndrome	5.72e-06	0.000114	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	5.7e-06	0.000114	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	5.68e-06	0.000113	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NGF—epilepsy syndrome	5.65e-06	0.000113	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	5.65e-06	0.000113	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	5.61e-06	0.000112	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	5.6e-06	0.000112	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—YWHAZ—epilepsy syndrome	5.59e-06	0.000112	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	5.59e-06	0.000112	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NGF—epilepsy syndrome	5.53e-06	0.00011	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCR5—epilepsy syndrome	5.5e-06	0.00011	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HTR2A—epilepsy syndrome	5.38e-06	0.000107	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCR5—epilepsy syndrome	5.38e-06	0.000107	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AGT—epilepsy syndrome	5.34e-06	0.000106	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	5.32e-06	0.000106	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—BCHE—epilepsy syndrome	5.3e-06	0.000106	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HTR2A—epilepsy syndrome	5.26e-06	0.000105	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—APOE—epilepsy syndrome	5.23e-06	0.000104	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TSC2—epilepsy syndrome	5.11e-06	0.000102	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	5.11e-06	0.000102	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AGT—epilepsy syndrome	5.11e-06	0.000102	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	5.1e-06	0.000102	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	5.05e-06	0.000101	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APOE—epilepsy syndrome	5e-06	9.99e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TSC2—epilepsy syndrome	5e-06	9.98e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	5e-06	9.98e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AGT—epilepsy syndrome	5e-06	9.97e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TH—epilepsy syndrome	4.98e-06	9.94e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	4.9e-06	9.79e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KDR—epilepsy syndrome	4.9e-06	9.79e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APOE—epilepsy syndrome	4.89e-06	9.77e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	4.89e-06	9.77e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—BCHE—epilepsy syndrome	4.87e-06	9.73e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	4.85e-06	9.68e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—BCHE—epilepsy syndrome	4.83e-06	9.64e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KDR—epilepsy syndrome	4.8e-06	9.57e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PRKCB—epilepsy syndrome	4.72e-06	9.42e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6ST—epilepsy syndrome	4.7e-06	9.38e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	4.65e-06	9.28e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PRKCB—epilepsy syndrome	4.62e-06	9.21e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	4.61e-06	9.2e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	4.6e-06	9.18e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6ST—epilepsy syndrome	4.6e-06	9.18e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TH—epilepsy syndrome	4.58e-06	9.15e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	4.56e-06	9.1e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TH—epilepsy syndrome	4.54e-06	9.07e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—POMC—epilepsy syndrome	4.49e-06	8.96e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	4.47e-06	8.93e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—POMC—epilepsy syndrome	4.3e-06	8.58e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCL2—epilepsy syndrome	4.21e-06	8.4e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—POMC—epilepsy syndrome	4.2e-06	8.39e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	4.16e-06	8.3e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCL2—epilepsy syndrome	4.11e-06	8.21e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CAT—epilepsy syndrome	4.1e-06	8.19e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ALB—epilepsy syndrome	4.09e-06	8.17e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	3.99e-06	7.97e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	3.82e-06	7.63e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGF2—epilepsy syndrome	3.8e-06	7.59e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	3.79e-06	7.57e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CAT—epilepsy syndrome	3.77e-06	7.53e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CAT—epilepsy syndrome	3.74e-06	7.47e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGF2—epilepsy syndrome	3.72e-06	7.42e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GPX1—epilepsy syndrome	3.71e-06	7.4e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	3.67e-06	7.33e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	3.64e-06	7.26e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—epilepsy syndrome	3.58e-06	7.15e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RELA—epilepsy syndrome	3.53e-06	7.04e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MTOR—epilepsy syndrome	3.46e-06	6.91e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RELA—epilepsy syndrome	3.45e-06	6.89e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GPX1—epilepsy syndrome	3.41e-06	6.81e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MTOR—epilepsy syndrome	3.38e-06	6.76e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GPX1—epilepsy syndrome	3.38e-06	6.75e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AGT—epilepsy syndrome	3.25e-06	6.49e-05	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT1—epilepsy syndrome	3.21e-06	6.41e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—APOE—epilepsy syndrome	3.19e-06	6.36e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CASP3—epilepsy syndrome	3.18e-06	6.35e-05	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT1—epilepsy syndrome	3.14e-06	6.27e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CASP3—epilepsy syndrome	3.11e-06	6.21e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUN—epilepsy syndrome	3.09e-06	6.17e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUN—epilepsy syndrome	3.02e-06	6.04e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—epilepsy syndrome	3.01e-06	6e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AGT—epilepsy syndrome	2.99e-06	5.97e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AGT—epilepsy syndrome	2.97e-06	5.92e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—epilepsy syndrome	2.94e-06	5.87e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—APOE—epilepsy syndrome	2.93e-06	5.85e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT1—epilepsy syndrome	2.92e-06	5.82e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—APOE—epilepsy syndrome	2.91e-06	5.8e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT1—epilepsy syndrome	2.85e-06	5.7e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SRC—epilepsy syndrome	2.77e-06	5.53e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—POMC—epilepsy syndrome	2.74e-06	5.47e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SRC—epilepsy syndrome	2.71e-06	5.41e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—epilepsy syndrome	2.7e-06	5.39e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—epilepsy syndrome	2.64e-06	5.27e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—POMC—epilepsy syndrome	2.52e-06	5.03e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—POMC—epilepsy syndrome	2.5e-06	4.98e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALB—epilepsy syndrome	2.5e-06	4.98e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALB—epilepsy syndrome	2.3e-06	4.58e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALB—epilepsy syndrome	2.28e-06	4.54e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	2.18e-06	4.36e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	2.01e-06	4.01e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	1.99e-06	3.97e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKT1—epilepsy syndrome	1.8e-06	3.59e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT1—epilepsy syndrome	1.72e-06	3.44e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT1—epilepsy syndrome	1.69e-06	3.36e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKT1—epilepsy syndrome	1.1e-06	2.19e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKT1—epilepsy syndrome	1.01e-06	2.02e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKT1—epilepsy syndrome	1e-06	2e-05	CbGpPWpGaD
